Products Affected - Description
Bactroban 2% nasal ointment, GlaxoSmithKline
1 gram tube, 10 count (NDC 00029-1526-11)
Reason for the Shortage
GlaxoSmithKline states the shortage is due to manufacturing issues.1
There are no presentations available.
Estimated Resupply Dates
GlaxoSmithKline has Bactroban Nasal 2% Ointment in 1 gram tubes on back order and the company estimates a release date of 1st quarter 2017.1
Implications for Patient Care
Mupirocin calcium ointment is used intranasally to eradicate nasal colonization of methicillin-resistant Staphylococcus aureus in adult patients and healthcare workers during institutional outbreaks to reduce the risk of infection.2
Do not share tubes of mupirocin ointment between patients to minimize the risk of cross-contamination.
Alternative Agents & Management
During this shortage, consider using mupirocin ointment instead of mupirocin calcium ointment.
- GlaxoSmithKline (personal communications). August 5, 2016.
- GlaxoSmithKline. Bactroban Nasal (mupirocin calcium) ointment 2% [product labeling]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
Updated August 6, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 13, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins